Anti-Hypertensive Drugs Non-Specifically Reduce “Spontaneous” Activation of Blood Platelets

Summary

Abnormal activation of blood platelets may be a contributory factor in the accelerated vascular disease which occurs in hypertension. We investigated the effects of lowering blood pressure in 12 patients with mild hypertension on several aspects of platelet function, initially in a placebo-controlled, double-blind, crossover study with nisoldipine, and subsequently in the same patients comparing nisoldipine with the patients’ usual anti-hypertensive therapy. Values were compared with those from an age, sex-matched control population. Seven hypertensive patients with renal failure were also studied. Administration of nisoldipine reduced ex vivo “spontaneous” aggregation of blood platelets significantly, and a similar significant effect was seen when blood pressure was lowered by the patients usual anti-hypertensive therapy. “Spontaneous” aggregation occurring in the control population was similar to that in the treated hypertensives. Blood platelet count, and aggregation in response to ADP and adrenalin were unaffected by treatment. Median plasma beta thromboglobulin levels were significantly higher in the untreated hypertensive patients (43 ng ml^-1) than in the controls (30 ng ml^-1), and there was a trend to reduced values for beta thromboglobulin on treatment of the hypertension. These results indicate that blood platelet activity is enhanced in hypertension and that function returns towards normal when blood pressure is lowered by treatment.

Keywords

“Spontaneous” platelet aggregation - Blood pressure - Beta-thromboglobulin - Nisoldipine

• References

• 1 Veterans Administration Cooperative Study Group. Effect of treatment on morbidity in hypertension. JAMA 1970; 213: 1143
• 2 Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J 1985; 291: 97
• 3 Hamet P, Skuherska R, Pang SC, Tremblay J. Abnormalities of platelet function in hypertension and diabetes. Hypertension 1985; 7 (6 pt 1) 972-978
• 4 Mehta J, Mehta P. Platelet function in hpyertension and effect of therapy. Am J Cardiol 1981; 47: 331-334
• 5 Vlachakis ND, Aledort L. Hypertension and propanolol therapy: Effect on blood pressure, plasma catecholamines and platelet aggregation. Am J Cardiol 1980; 45: 321-325
• 6 Ikeda T, Nonaka Y, Goto A, Ishii M. Effects of prazocin on platelet aggregation and beta-thromboglobulin in essential hypertension. Clin Pharmacol Therapeut 1985; 37: 601-605
• 7 Erne P, Bolli P, Burgisser E, Buhler FR. Correlation of platelet calcium with blood pressure. N Engl J Med 1984; 310: 1084-1088
• 8 Luque Otero M, Fernandez Pinilla C, Escriba Polo A, Rodriguez Vazquez M, Martell Claros N, Femandez-Cruz A. The effect of two beta-adrenoceptor blockers (mepindolol and atenolol) on blood lipids and platelet aggregation in normal volunteers and essential hypertensive patients. Br J Clin Pharmacol 1984; 17 (03) 361-363
• 9 Greer IA, Walker JJ, Calder AA, Forbes CD. Inhibition of platelet aggregation in whole blood by adrenoceptor antagonists. Thromb Res 1985; 40 (05) 631-643
• 10 Jones CR, Pasanisi F, Elliot HL, Reid JL. Effects of verapamil and nisoldipine on human platelets: in vivo and in vitro studies. Br J Clin Pharmacol 1985; 20 (03) 191-196
• 11 Someya N, Morotomi Y, Kodama K, Kida O, Higa T, Kondo K, Tanaka K. Suppressive effect of captopril on platelet aggregation in essential hypertension. J Cardiovasc Pharmacol 1984; 6 (05) 840-843
• 12 Evans EP, Branch RA. Bloom ALA clinical and experimental study of platelet function in chronic renal failure. J Clin Pathol 1972; 25: 745-753
• 13 Butcher J, Humphrey PP A, Hyde JJ, Lumley P, Spurling NW. The evaluation of a new electronic counting technique for measurement of platelet aggregation in human whole blood in vitro. Br J Pharmacol 1980; 70: 160
• 14 Lumley P, Humphrey PP A. A method for quantitating platelet aggregation and analysing drug-receptor interactions on platelets in whole blood. J Pharmacol Methods 1981; 6: 153-166
• 15 Saniabadi AR, Lowe GD O, Forbes CD, Prentice CRM, Barbenel JC. Platelet aggregation studies in whole human blood. Thromb Res 1983; 30: 625-632
• 16 Han P, Ardlie NG. The influences of pH, temperature and calcium on platelet aggregation. Br J Haematol 1974; 26: 373-389
• 17 Siegel S. Nonparametric Statistics for the Behavioral Sciences. McGraw-Hill Kogakusha Ltd; Tokyo: 1957: 14-52
• 18 Lande K, Kjeldsen SE, Eide I, Leren P, Gjesdal K. Does increased platelet release normalize during anti-hypertensive treatment?. Thromb Haemostas 1987; 58 (03) 834-838
• 19 Shinjo A, Sasaki Y, Inamasu M, Morita T. In vitro effect of the coronary vasodilator diltiazem on human and rabbit platelets. Thromb Res 1978; 13: 941-955
• 20 Saniabadi AR, Lowe GD O, Barbenel JC, Forbes CD. A comparison of spontaneous platelet aggregation in whole blood with platelet rich plasma: additional evidence for the role of ADP. Thromb Haemostas 1984; 51 (01) 115-118
• 21 Sanaibadi AR, Lowe GD O, Barbenel JC, Forbes CD. Further studies on the role of red blood cells in spontaneous platelet aggregation. Thromb Res 1985; 38: 225-232
• 22 Riozzi A, Heagerty AM, Ollerenshaw JD, Swales JD. Erythrocyte phosphoinositide metabolism in essential hypertensive patients and their normotensive offspring. Clin Sci 1987; 73: 29-32
• 23 Bing RF, Heagerty AM, Thurston H, Swales JD. Ion transport in hypertension: are changes in the cell membrane responsible?. Clin Sci 1986; 71: 225-230
• 24 Franco-Morselli R, Elghozi JL, Joly E, Di Giuilo S, Meyer P. Increased plasma adrenaline concentrations in benign essential hypertension. Br Med J 1977; 2: 1251-1254
• 25 Biondi ML, Agostoni A, Marasini B. Serotonin levels in hypertension. J Hypertension (Suppl) 1986; 4 (01) S39-S41
• 26 Cowley AW, Cushman WC, Quillen EW, Shelton MM, Langford HG. Vasopressin elevation in essential hypertension and increased responsiveness to sodium intake. Hypertension 1981; (Suppl I) I: 93-100
• 27 Lande K, Os I, Kjeldsen SE, Westheim A, Aakesson I, Hjermann I, Eide I, Gjesdal K. Patients with mild essential hypertension have increased platelet size and release reaction and show increased receptor response to infused adrenaline. Thromb Haemostas 1987; 58 (01) 399 (Abstr 1462)
• 28 Zahavi J, Kakkar VV. Beta-thromboglobulin, a specific marker of in-vivo platelet release reaction. Thromb Haemostas 1980; 44: 23-29
• 29 Lindner A, Kenny M, Meacham AJ. Effects of a circulating factor in patients with essential hypertension on intra-cellular free calcium in normal platelets. N Engl J Med 1987; 316: 509-513
• 30 Brodde OE, Stuka N, Demuth V, Fesel R, Bergerhausen J, Daul A, Bock KD. Alpha- and beta-adrenoreceptors in circulating blood cells of essential hypertensive patients. Increased receptor density and responsiveness. Clin Exp Hypertens (A) 1985; 7: 1135-1150
• 31 Nyrop M, Zweifler AJ. Platelet aggregation in hypertension and the effect of antihypertensive treatment. J Hypertension 1988; 6: 263-269
• 32 Abrahamsen AF. Platelet survival studies in man with special reference to thrombosis and atherosclerosis. Scand J Haematol 1968; Suppl (Suppl. 03) 7-53
• 33 Vlachakis ND, Aledort L. Platelet lipid peroxides as determinant of platelet survival and sympathetic stimulation in patients with hypertension. Biochem Med 1979; 21: 94-103